Clinical trial Archives

News and Trends 6 Jul 2023

Positive data from Sensorion hearing loss study

Sensorion, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has reported further analysis from its Proof of Concept (POC) phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation. In June 19, Sensorion announced that in preliminary […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy. […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

Best in Biotech 21 Jun 2023

Five latest advancements in osteoporosis research

Osteoporosis is a condition that causes bones to become extremely weak, making them more likely to break. In fact, in extremely serious cases of osteoporosis, even a cough or a minor bump can result in a fracture. Often referred to as a ‘silent disease’, many people who develop the condition will not be aware they […]

June 21, 2023 - 8 minutesmins - By Willow Shah-Neville

News and Trends 20 Jun 2023

NodThera announces positive inflammatory disease data

NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a highly validated drug target that plays a pivotal role in controlling inflammatory diseases. The differentiated design characteristics of each candidate enabled them to penetrate different […]

June 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jun 2023

Lighting up cancer: FluoGuide announces positive results from head & neck cancer trial

FluoGuide A/S, a Danish biotech company, has announced positive interim results from the phase IIa trial of its lead product FG001 in head & neck cancer. FG001 was shown to illuminate tumors in all of the patients. Data show all 12 patients in the first two cohorts, undergoing surgery for head & neck squamous cell […]

June 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jun 2023

FDA puts hold on Arcellx myeloma program following patient death

Arcellx, Inc. has received notification from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on its CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). The clinical hold was received on June 16, following a recent patient death. The company said […]

June 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Jun 2023

Allgenesis says dry eye patients’ trial data ‘encouraging’

Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, has announced topline data from its phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of dry eye disease (DED). AG-80308 was considered safe at all doses […]

June 19, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 19 Jun 2023

Trial shows colorectal cancer drug efficacy

HUTCHMED (China) Limited and Takeda have announced results of their phase III FRESCO‑2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC), which were published in The Lancet. Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3. FRESCO-2 is a global phase […]

June 19, 2023 - 6 minutesmins - By Jim Cornall

induced pluripotent stem cells ipsc Alzheimer's

News and Trends 13 Jun 2023

‘Clinical trial in a dish’ for Alzheimer’s disease

Axol Bioscience Ltd., a pluripotent stem cell technology provider for drug discovery, has signed an agreement with StrataStem to access and commercialize its collection of Alzheimer’s disease (AD) patient samples. Harnessing its stem cell knowledge, Axol will reprogram these patient samples into induced pluripotent stem cells (iPSCs) that can then be differentiated into a wide […]

June 13, 2023 - 3 minutesmins - By Jim Cornall

Best in Biotech 12 Jun 2023

Six advancements in Alzheimer’s research over the past year

The most common cause of dementia, Alzheimer’s disease, is a brain disorder that is characterized by cognitive decline which often manifests itself through memory loss, feelings of disorientation and difficulty making decisions. Alzheimer’s occurs when there is an excessive accumulation of proteins in the brain, a hallmark feature of the disease. These proteins, namely, amyloid […]

June 12, 2023 - 12 minutesmins - By Roohi Mariam Peter

News and Trends 9 Jun 2023

Med-Life Discoveries to start rare pediatric disease trial

Med-Life Discoveries, LP (MLD) is a Canadian biopharmaceutical company dedicated to advancing a therapy to reduce symptoms for a devastating pediatric rare disease, Rhizomelic chondrodysplasia punctata (RCDP), which causes significant physical and neurological delays in children who inherit it. Med-Life Discoveries has received a no objection letter (NOL) from Health Canada to begin a phase […]

June 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 8 Jun 2023

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD). X-ALD is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately six to eight per 100,000 live births. […]

June 8, 2023 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Positive data from Sensorion hearing loss study

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Five latest advancements in osteoporosis research

NodThera announces positive inflammatory disease data

Lighting up cancer: FluoGuide announces positive results from head & neck cancer trial

FDA puts hold on Arcellx myeloma program following patient death

Allgenesis says dry eye patients’ trial data ‘encouraging’

Trial shows colorectal cancer drug efficacy

‘Clinical trial in a dish’ for Alzheimer’s disease

Six advancements in Alzheimer’s research over the past year

Med-Life Discoveries to start rare pediatric disease trial

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!